New antibody sits at the center of this dementia and brain health question.

New antibody therapies are actively moving through clinical development for Alzheimer’s disease, offering a different approach than the immunotherapies already approved by the FDA. As of 2025-2026, the field has expanded significantly beyond lecanemab (Leqembi), which became the first anti-amyloid monoclonal antibody approved for maintenance IV dosing in July 2025. Multiple promising candidates are now in Phase 2 and Phase 3 trials, with some showing remarkable early results—for instance, trontinemab achieved amyloid negativity in 91% of subjects receiving the highest dose at 28 weeks, with a brain bleed rate below 5%.

This article examines what these new antibody therapies are, how they differ from existing options, what the clinical trial data shows, and what developments are expected in the coming years. The expansion of the antibody therapy pipeline reflects a fundamental shift in how researchers approach Alzheimer’s. Rather than a single approach, the field is now testing multiple strategies: direct amyloid targeting, tau protein removal, bispecific antibodies that hit two targets simultaneously, and therapies addressing neuroinflammation. With 138 drugs currently being assessed across 182 clinical trials worldwide, the next few years will likely bring answers about which therapies work best for which patients.

What Are Antibody Therapies Targeting in Alzheimer’s Disease?
How Effective Are These New Antibody Therapies, and What Are the Safety Concerns?
How Do New Monoclonal Antibodies Compare to Each Other?
What Does Clinical Development Mean, and How Long Does It Take?
What Are the Safety Limitations and Who Might Not Be Candidates?
What’s the Status of Tau-Targeting Antibody Development?
What’s the Broader Pipeline, and What Should Patients Expect?
Conclusion

What Are Antibody Therapies Targeting in Alzheimer’s Disease?

Antibody therapies for Alzheimer’s work by targeting proteins believed to drive neurodegeneration. The two main targets are amyloid-beta (Aβ), the protein that accumulates in plaques between brain cells, and tau, the protein that tangles inside neurons. Leqembi, already approved, targets amyloid-beta. Newer therapies in development are pursuing both targets, either as single antibodies focused on one protein or as bispecific antibodies designed to bind both amyloid and tau simultaneously. The distinction matters because different patients may benefit from targeting different proteins. Early Alzheimer’s disease often involves significant amyloid accumulation, while tau pathology becomes more prominent as the disease progresses.

A patient with evidence of amyloid buildup but minimal tau tangles might respond better to amyloid-focused therapy, whereas someone further along might need a dual approach. This is why researchers are testing such a diverse range of candidates—there isn’t yet a one-size-fits-all solution. Bispecific antibodies represent a newer frontier. As of May 2025, no bispecific antibodies for Alzheimer’s have reached the market, but multiple candidates are in preclinical and early clinical development. The theoretical advantage is efficiency: one molecule that targets two different parts of the pathology. However, this complexity also means longer development timelines and more variables to test in clinical trials.

What Are Antibody Therapies Targeting in Alzheimer's Disease?

How Effective Are These New Antibody Therapies, and What Are the Safety Concerns?

The early-phase data for trontinemab is striking. In a Phase 1b/2a trial of 114 subjects, 91% of those receiving the highest dose achieved amyloid negativity at 28 weeks—meaning their brains showed no evidence of amyloid accumulation on PET imaging. This level of amyloid clearing is substantially higher than historical rates. Even more encouraging, the trial recorded less than a 5% incidence of brain bleeds or amyloid-related imaging abnormalities (ARIA), the most serious side effect seen with some anti-amyloid therapies. However, this doesn’t mean the therapy is without risks. Some anti-amyloid antibodies, including lecanemab, do carry risks of brain microhemorrhages and amyloid-related imaging abnormalities, particularly in patients carrying the APOE4 genetic variant, which is associated with increased Alzheimer’s risk.

The low ARIA rate in trontinemab’s early trials is encouraging, but it’s too early to declare the problem solved. Phase 3 trials (TRONTIER 1 and 2) planned for 2025 will involve larger, more diverse patient populations and longer follow-up periods—the real test of safety. It’s also worth noting that amyloid negativity on imaging doesn’t automatically translate to clinical improvement. While removing amyloid from the brain is believed to slow cognitive decline, the relationship isn’t perfectly linear. Some patients with cleared amyloid may still experience cognitive changes, while others may show meaningful slowing of decline. This uncertainty is why longer-term clinical outcomes, not just imaging results, are what ultimately matter.

How Do New Monoclonal Antibodies Compare to Each Other?

Leqembi, approved in July 2025 for IV maintenance dosing, has established some baseline expectations for the class. It’s an amyloid-targeting monoclonal antibody with proven clinical efficacy—it slows cognitive decline in early Alzheimer’s disease, though the effect size is modest (roughly 35% slowing of decline over 18 months in trial populations). The trade-off is convenience balanced against safety: it requires biweekly infusions, AMYVID PET imaging confirmation of amyloid pathology before starting, and regular MRI monitoring for ARIA. Trontinemab takes a different technological approach. Rather than the standard monoclonal antibody design, it uses what’s called Brainshuttle technology, a delivery mechanism designed to more efficiently cross the blood-brain barrier and reach amyloid deposits in the brain.

Early results suggest this may translate to higher amyloid clearance rates, which is why the 91% amyloid negativity figure stands out. However, Brainshuttle is less established clinically than the traditional monoclonal approach, so there are more unknowns about long-term tolerability and real-world effectiveness. This is where Phase 3 trials become critical. TRONTIER 1 and 2 will compare trontinemab to placebo in much larger populations and track not just amyloid imaging but actual cognitive outcomes over time. Until those results are published, it’s premature to say whether the superior amyloid-clearing ability translates to better patient outcomes than Leqembi.

How Do New Monoclonal Antibodies Compare to Each Other?

What Does Clinical Development Mean, and How Long Does It Take?

When an antibody therapy “enters clinical development,” it’s moving from laboratory and animal testing into human studies, but it’s still years away from being prescribed routinely. The typical pathway involves several phases: Phase 1 focuses on safety and dosing in small groups (usually 20-100 people), Phase 2 tests efficacy and identifies side effects in larger groups (100-500 people), and Phase 3 confirms efficacy and monitors adverse effects in even larger populations (1,000+ people) across multiple sites. Trontinemab has completed Phase 1b/2a trials and is advancing toward Phase 3, which means researchers have already seen encouraging safety and amyloid-clearing signals. However, Phase 3 trials typically take 1-3 years to complete, and then regulatory review adds additional time.

Even with accelerated pathways, we’re likely looking at 2027-2028 before trontinemab could potentially reach the market—if all goes well. Delays are common; unforeseen safety issues or efficacy concerns can extend timelines significantly. The broader Alzheimer’s pipeline includes multiple therapies at different stages. Tau-targeting antibodies like E2814 (etalanetug), posdinemab, BMS-986446, and MK-2214 are expected to report Phase 2 data by the end of 2025, meaning we’ll have a much clearer picture of which tau-targeting approaches are most promising by next year.

What Are the Safety Limitations and Who Might Not Be Candidates?

Amyloid-related imaging abnormalities (ARIA) remain the primary safety concern for anti-amyloid antibodies, regardless of the specific drug. ARIA manifests as either microhemorrhages (brain bleeds) or microinfarcts and brain swelling (edema). While trontinemab’s <5% ARIA rate is lower than some alternatives, it's not zero, and rarer serious events may only emerge once drugs are used in millions of people over years. Genetic risk factors significantly influence ARIA susceptibility. Patients who carry one or two copies of the APOE4 allele face substantially higher ARIA risk. For this reason, genetic testing before starting anti-amyloid therapy is standard practice.

A patient with two copies of APOE4 might be advised to start at lower doses, receive more frequent MRI monitoring, or in some cases be excluded from treatment entirely. This creates an equity issue: APOE4 is more common in people of African descent, meaning some populations may face different risk-benefit calculations for the same therapy. Additionally, these therapies are only intended for early symptomatic or preclinical stages of Alzheimer’s. They’re not indicated for patients with advanced dementia, where amyloid pathology is established but neurodegeneration is already widespread. Someone who has had cognitive decline for several years may have missed the window where amyloid removal provides benefit. This is why early diagnosis and enrollment in trials is so critical—these therapies work best if given before too much neuronal damage has occurred.

What Are the Safety Limitations and Who Might Not Be Candidates?

What’s the Status of Tau-Targeting Antibody Development?

While amyloid-targeting antibodies have moved furthest along (with Leqembi already approved), tau-targeting therapies are close behind. Tau accumulation is often more closely correlated with cognitive symptoms and neuronal death than amyloid is, so tau-targeting agents could potentially address later stages of Alzheimer’s. Several candidates are in Phase 2 development: E2814/etalanetug, posdinemab, BMS-986446, and MK-2214.

Phase 2 data for these therapies is expected by the end of 2025, which will provide the first human evidence of whether tau targeting translates to clinical benefit. Unlike amyloid, which has been extensively studied since the 1990s, tau immunotherapy is newer territory. The field will be watching closely to see whether tau-targeting antibodies can slow cognitive decline and, critically, whether they have a better safety profile than amyloid-targeting approaches.

What’s the Broader Pipeline, and What Should Patients Expect?

The scale of antibody therapy development is remarkable. As of 2025-2026, researchers are assessing 138 different drugs across 182 clinical trials for Alzheimer’s disease. This isn’t just monoclonal antibodies; it includes bispecific agents, tau-targeting therapies, neuroinflammation modulators, and other mechanisms. The field is explicitly moving away from a single-solution approach toward precision medicine—identifying which patients are most likely to benefit from which therapies.

Bispecific antibodies, which remain in preclinical development as of May 2025, could represent the next generation. These molecules simultaneously target amyloid, tau, or neuroinflammatory pathways. If successful, a single bispecific antibody might address multiple pathways driving neurodegeneration, potentially offering better outcomes than targeting one protein alone. However, these are more complex molecules with longer development timelines, so they’re unlikely to reach patients within the next 3-4 years.

Conclusion

New antibody therapies represent a genuine expansion of Alzheimer’s treatment options. Leqembi is already available, trontinemab is advancing toward Phase 3 trials with strong early safety and efficacy signals, and tau-targeting antibodies are expected to generate Phase 2 data by late 2025. These therapies work best when given early—in preclinical or mild cognitive impairment stages—before extensive neuronal damage occurs, which makes early detection and diagnosis increasingly critical.

For patients and families, the key takeaway is that this landscape is changing rapidly. If you or a family member are showing early signs of cognitive decline, discussing amyloid and tau PET imaging with a neurologist or memory specialist is now a reasonable conversation. The therapies available today are imperfect—they slow decline rather than reversing it—but they represent meaningful progress. Staying informed about trials and new approvals, especially as Phase 3 data and tau-targeting results emerge over the next 1-2 years, will help patients make informed decisions about treatment options as they become available.